Oliver Schon

Bessemer Venture Partners LP seeks investment opportunities in companies primarily located in the US. The fund focuses on companies with a strong business model, experienced management teams and growth potential. It targets companies operating across a broad range of sectors such as healthcare, information systems, telecommunications, and retailing. It provides financing for seed, early and later stage capital requirements.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom.

Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Part of Novacyt SAS, Biotec Laboratories Ltd. is a British company that produces and distributes diagnostic reagents, test kits and dehydrated culture media. The company is based in Ipswich, UK. Biotec Laboratories was acquired by Lab 21 Ltd. on March 03, 2009.

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

Joh. Berenberg, Gossler & Co. KG (United Kingdom) (Berenberg-UK) is the Great Britain-based broker/dealer division of Joh. Berenberg, Gossler & Co. KG, a multinational full-service investment bank in Germany. Headquartered in London, Berenberg-UK was founded in 2003 and provides trading and brokerage services to institutional and corporate clients.

Lab 21 Ltd. operates as a healthcare diagnostics company. It specializes in providing patients, doctors, hospitals ,and healthcare providers with diagnostic information for disease identification, disease predisposition, and personalized medicine, to help in managing health problems. It also offers diagnostic products and services and supports blood bank screening, medical diagnostics, and drug discovery. The company was founded in April 2005 by Berwyn E. Clarke and is headquartered in Cambridge, the United Kingdom.

Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Microgen Bioproducts Ltd. develops, manufactures, distributes, and markets clinical laboratory products. It offers biochemical identification and latex agglutination kits, path-check hygiene and pregnancy tests, pulsifier, and bacterial typing antisera. The company was founded in 1994 and is headquartered in Camberley, the United Kingdom.

Kowa Pharmaceutical Europe Co. Ltd. engages in the manufacture of pharmaceutical products. The company was founded in 1947 and is headquartered in Wokingham, the United Kingdom.

The Electrospinning Co. Ltd. develops and manufactures electro spun polymer scaffolds. The firm offers Minetix 3D tissue culture plates. It sell a range of ready-to-use, sterile tissue culture plates containing the Mimetix scaffold for tissue engineering, regenerative medicine and drug discovery research. The company was founded by Robert Stevens and David Mansel Williams in 2010 and is headquartered in Didcot, the United Kingdom.

Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland.

Blueberry Therapeutics Ltd. engages in the development of innovative medicines. It offers nanomedicine, anti infection and anti microbial, anti inflammatory bowel diseases, acne, dermatitis and wound medicines. The company was founded by John Ridden and Mike Davies and is headquartered in Macclesfield, the United Kingdom.

Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom.

Part of Abbott Laboratories, TwistDx Ltd. is a British company that specializes in recombinase polymerase amplification technology. The company is based in Maidenhead, UK. The company offers TwistAmp research kits for researchers to develop tests, assays, and kits relevant to their work in fields such as water testing, biodefense, food species verification, and clinical or veterinary diagnostics. The company can work with partners on specific assay development collaborations for research and commercial applications. The company offers devices and accessories for research and development use only. The company was founded in 2002 by Niall Armes, Derek Stemple, Nagesh K. Mahanthappa.

Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA.

Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming.

Nereid Therapeutics, Inc. operates as a life sciences venture firm. It translates the potential of biomolecular condensates into life-changing therapeutics. The company was founded by Clifford Brangwynne and Spiros Liras and is headquartered in Cambridge, MA.

Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019.

Kowa Research Europe Ltd. engages in research and experimental development on social sciences and humanities. The firm develops NK-104, Pitavastatin; K-877, Pemafibrate; K-333, Peretinoin; and K-115, Ripasudil compounds. The company was founded on January 12, 1999 and is headquartered in Wokingham, the United Kingdom.